ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
WEDNESDAY, Oct. 25, 2023 -- For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | HER2 | Herceptin | Pharmaceuticals | Study